Project Grant R43GM165336
Award Date 9/15/26
Completion Date 3/14/27
Dollars Obligated $221K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19103, USA
Similar Awards
- The National Center for Advancing Translational Sciences awarded Goeppert LLC, a Philadelphia-based small disadvantaged business, $350,000 on July 1, 2026, under CFDA 93.350 (National Center for Advancing Translational Sciences) to develop NANO-PAVE, a nanopore-based platform for assessing adeno-associated virus (AAV) capsid quality in gene therapy manufacturing. NANO-PAVE addresses a critical bottleneck in AAV clinical translation: current quality-control assays (ELISA, ddPCR, analytical...
- The National Institutes of Health National Center for Advancing Translational Sciences awarded $306,872 to Endless Vectors Bioscience on September 3, 2026, under the NCATS Program (CFDA 93.350) to develop and validate a cell cycle-dependent replicating adeno-associated virus platform for treating neonatal inborn errors of metabolism. Endless Vectors will assess tissue-specific replication, episomal persistence, and long-term safety and efficacy of the CCRAAV platform in neonatal mouse liver...
- The National Institute of General Medical Sciences awarded the University of Massachusetts Medical School $1,675,000 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to interrogate the roles of truncated and mutated inverted terminal repeat (ITR) sequences in adeno-associated virus (AAV) vectors and their effects on transgene stability through episome formation and host cell genome integration. The project, designated R01GM155648, addresses a critical gap...
- The National Institute of General Medical Sciences awarded $300,001 to Vivid Bioinnovations, PBC on August 4, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop an integrated micro-robotic screening platform for high-throughput chemical reaction optimization and artificial intelligence model training. Vivid Bioinnovations will engineer a scalable platform combining micro-robotic nanoliter droplet dispensing with custom nanowell arrays and matrix-assisted...
- The National Institute of Allergy and Infectious Diseases awarded Neovaxsyn Inc. $300,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel recombinant adeno-associated virus (rAAV) production system optimized for gene therapy and vaccine applications. Neovaxsyn will design, generate, and evaluate a baculoviral expression system called OneBacMid that enables rAAV assembly in mammalian cells, aiming to improve both quality and...
- The National Institute of General Medical Sciences awarded The Ohio State University $386,105 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate adeno-associated virus (AAV) biology, genome persistence, and the translation of AAV persistence mechanisms to synthetic gene-delivery substrates. The research addresses three core questions: the fate of AAV genomes across human tissues and the molecular features of episomal AAV; whether...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Vecgen, Inc. $333,689 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop and validate a diagnostic tool predicting immune responses to adeno-associated virus (AAV) gene therapies. Vecgen will clone and produce a comprehensive set of AAV vectors carrying FDA-approved gene therapy sequences and establish standardized immunogenicity benchmarks using...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
- The National Institute of Neurological Disorders and Stroke awarded The Broad Institute, Inc. $404,282 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to engineer transferrin receptor 1 (TFR1) binding adeno-associated virus (AAV) capsids that evade pre-existing neutralizing antibodies while maintaining central nervous system delivery capability. The funded research addresses a critical barrier to AAV gene therapy for...
- The National Science Foundation Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded the University of Texas at Arlington $300,000 on September 1, 2026, for collaborative research in multimodal nanopore biosensing and nanosieving for upstream quality control of adeno-associated virus gene therapy vectors under the Engineering program (CFDA 47.041). The project will develop an integrated optical-electrical nanopore biosensing platform to detect and quantify...